These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 12852746)

  • 1. An orally bioavailable oxime ether capsid binder with potent activity against human rhinovirus.
    Watson KG; Brown RN; Cameron R; Chalmers DK; Hamilton S; Jin B; Krippner GY; Luttick A; McConnell DB; Reece PA; Ryan J; Stanislawski PC; Tucker SP; Wu WY; Barnard DL; Sidwell RW
    J Med Chem; 2003 Jul; 46(15):3181-4. PubMed ID: 12852746
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 2-Ethoxybenzoxazole as a bioisosteric replacement of an ethyl benzoate group in a human rhinovirus (HRV) capsid binder.
    Brown RN; Cameron R; Chalmers DK; Hamilton S; Luttick A; Krippner GY; McConnell DB; Nearn R; Stanislawski PC; Tucker SP; Watson KG
    Bioorg Med Chem Lett; 2005 Apr; 15(8):2051-5. PubMed ID: 15808466
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis and evaluation of novel chloropyridazine derivatives as potent human rhinovirus (HRV) capsid-binding inhibitors.
    Fan SY; Zheng ZB; Mi CL; Zhou XB; Yan H; Gong ZH; Li S
    Bioorg Med Chem; 2009 Jan; 17(2):621-4. PubMed ID: 19091578
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro activity of expanded-spectrum pyridazinyl oxime ethers related to pirodavir: novel capsid-binding inhibitors with potent antipicornavirus activity.
    Barnard DL; Hubbard VD; Smee DF; Sidwell RW; Watson KG; Tucker SP; Reece PA
    Antimicrob Agents Chemother; 2004 May; 48(5):1766-72. PubMed ID: 15105133
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 8. Pharmacological optimization of orally bioavailable 2-pyridone-containing peptidomimetics.
    Dragovich PS; Prins TJ; Zhou R; Johnson TO; Hua Y; Luu HT; Sakata SK; Brown EL; Maldonado FC; Tuntland T; Lee CA; Fuhrman SA; Zalman LS; Patick AK; Matthews DA; Wu EY; Guo M; Borer BC; Nayyar NK; Moran T; Chen L; Rejto PA; Rose PW; Guzman MC; Dovalsantos EZ; Lee S; McGee K; Mohajeri M; Liese A; Tao J; Kosa MB; Liu B; Batugo MR; Gleeson JP; Wu ZP; Liu J; Meador JW; Ferre RA
    J Med Chem; 2003 Oct; 46(21):4572-85. PubMed ID: 14521419
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis and antienteroviral activity of a series of novel, oxime ether-containing pyridyl imidazolidinones.
    Chern JH; Lee CC; Chang CS; Lee YC; Tai CL; Lin YT; Shia KS; Lee CY; Shih SR
    Bioorg Med Chem Lett; 2004 Oct; 14(20):5051-6. PubMed ID: 15380197
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antirhino/enteroviral vinylacetylene benzimidazoles: a study of their activity and oral plasma levels in mice.
    Tebbe MJ; Spitzer WA; Victor F; Miller SC; Lee CC; Sattelberg TR; McKinney E; Tang JC
    J Med Chem; 1997 Nov; 40(24):3937-46. PubMed ID: 9397174
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis and activity of piperazine-containing antirhinoviral agents and crystal structure of SDZ 880-061 bound to human rhinovirus 14.
    Oren DA; Zhang A; Nesvadba H; Rosenwirth B; Arnold E
    J Mol Biol; 1996 May; 259(1):120-34. PubMed ID: 8648640
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacophore-based design, synthesis, and biological evaluation of novel chloro-pyridazine piperazines as human rhinovirus (HRV-3) inhibitors.
    Wang H; Xiao J; Gao D; Zhang X; Yan H; Gong Z; Sun T; Li S
    Bioorg Med Chem Lett; 2011 Feb; 21(3):1057-9. PubMed ID: 21215622
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design, synthesis and in vitro evaluation of novel chroman-4-one, chroman, and 2H-chromene derivatives as human rhinovirus capsid-binding inhibitors.
    Conti C; Proietti Monaco L; Desideri N
    Bioorg Med Chem; 2011 Dec; 19(24):7357-64. PubMed ID: 22088306
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro characterisation of a pleconaril/pirodavir-like compound with potent activity against rhinoviruses.
    Lacroix C; Laconi S; Angius F; Coluccia A; Silvestri R; Pompei R; Neyts J; Leyssen P
    Virol J; 2015 Jul; 12():106. PubMed ID: 26169596
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro antiviral activity and single-dose pharmacokinetics in humans of a novel, orally bioavailable inhibitor of human rhinovirus 3C protease.
    Patick AK; Brothers MA; Maldonado F; Binford S; Maldonado O; Fuhrman S; Petersen A; Smith GJ; Zalman LS; Burns-Naas LA; Tran JQ
    Antimicrob Agents Chemother; 2005 Jun; 49(6):2267-75. PubMed ID: 15917520
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of lipophilicity modulation on inhibition of human rhinovirus capsid binders.
    Morley A; Tomkinson N; Cook A; MacDonald C; Weaver R; King S; Jenkinson L; Unitt J; McCrae C; Phillips T
    Bioorg Med Chem Lett; 2011 Oct; 21(20):6031-5. PubMed ID: 21907579
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis and antirhinovirus activity of new 3-benzyl chromene and chroman derivatives.
    Conti C; Desideri N
    Bioorg Med Chem; 2009 May; 17(10):3720-7. PubMed ID: 19398344
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 2. Peptide structure-activity studies.
    Dragovich PS; Webber SE; Babine RE; Fuhrman SA; Patick AK; Matthews DA; Reich SH; Marakovits JT; Prins TJ; Zhou R; Tikhe J; Littlefield ES; Bleckman TM; Wallace MB; Little TL; Ford CE; Meador JW; Ferre RA; Brown EL; Binford SL; DeLisle DM; Worland ST
    J Med Chem; 1998 Jul; 41(15):2819-34. PubMed ID: 9667971
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacophore modeling, docking, and principal component analysis based clustering: combined computer-assisted approaches to identify new inhibitors of the human rhinovirus coat protein.
    Steindl TM; Crump CE; Hayden FG; Langer T
    J Med Chem; 2005 Oct; 48(20):6250-60. PubMed ID: 16190752
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 1. Michael acceptor structure-activity studies.
    Dragovich PS; Webber SE; Babine RE; Fuhrman SA; Patick AK; Matthews DA; Lee CA; Reich SH; Prins TJ; Marakovits JT; Littlefield ES; Zhou R; Tikhe J; Ford CE; Wallace MB; Meador JW; Ferre RA; Brown EL; Binford SL; Harr JE; DeLisle DM; Worland ST
    J Med Chem; 1998 Jul; 41(15):2806-18. PubMed ID: 9667970
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Piperazinyl oxime ethers as NK-1 receptor antagonists.
    van den Hoogenband A; van Maarseveen JH; McCreary AC; Mulder AT; van Scharrenburg GJ; van Stuivenberg HH; Zethof TJ; Zijta B; Iwema Bakker WI
    Bioorg Med Chem Lett; 2006 Feb; 16(4):1045-8. PubMed ID: 16289817
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro activity of pirodavir (R 77975), a substituted phenoxy-pyridazinamine with broad-spectrum antipicornaviral activity.
    Andries K; Dewindt B; Snoeks J; Willebrords R; van Eemeren K; Stokbroekx R; Janssen PA
    Antimicrob Agents Chemother; 1992 Jan; 36(1):100-7. PubMed ID: 1317142
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis of new compounds with promising antiviral properties against group A and B Human Rhinoviruses.
    Bernard AM; Cabiddu MG; De Montis S; Mura R; Pompei R
    Bioorg Med Chem; 2014 Aug; 22(15):4061-6. PubMed ID: 24973816
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.